mutations and sophisticated kar yotype. It follows a linear evolution from the CLL clone with the recurrent acquisition of CDKN2A Not all sufferers with CLL need therapy. Despite all the latest advancements, the iwCLL nevertheless recommends watchful observation for people with asymptomatic condi